OncoMatch/Clinical Trials/NCT03290534
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
Is NCT03290534 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies CivaSheet for lung cancer.
Treatment: CivaSheet — This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage CLINICAL STAGE I, CLINICAL STAGE II
Clinical stage I or Clinical stage II
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- NYU Langone Health · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify